
With many benefits, AI technology does have the potential to change the way practices work in the coming years, but it may require additional advancements in terms of relieving physician burnout and driving organization.

With many benefits, AI technology does have the potential to change the way practices work in the coming years, but it may require additional advancements in terms of relieving physician burnout and driving organization.

The growing body of evidence that suggests that maintaining adequate levels of vitamin D may be beneficial for preventing and managing RVO.

In a study, Australian ophthalmology and optometry researcher and Beatles fan Professor Stephen Vincent has analyzed John Lennon’s little-known, hit-and-miss use of contact lenses in the 1960s and found the Rock and Roll Hall of Famer was probably right when he theorized that his cannabis use helped them stay in place.

EC-104 is a novel intravitreal (IVT) corticosteroid implant with intended 6 months durable drug release for the treatment of DME.

The growing body of evidence that suggests that maintaining adequate levels of vitamin D may be beneficial for preventing and managing RVO.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.


Stephen R. Russell, MD, discussed the 9-year data he presented at the American Society of Retina Specialists annual meeting for voretigene neparvovec-rzyl.

In English and Spanish TV and radio spots, the public is urged to protect their vision from preventable blindness and vision loss by seeking care from a retina specialist at the first sign of retinal disease.


Eastern Kentucky University student Madison Carlisle experienced rapid vision loss until the team at UK HealthCare was able to unravel the source of her issues.

Sadda is the second person to serve as chair. The first chairholder was John Irvine, MD, who was appointed to the role in 2001.

EC-104 is a novel intravitreal (IVT) corticosteroid implant with intended 6 months durable drug release for the treatment of DME.

Technologies continue to push retina surgical suites into the future

The NIH-funded study finds lack of coverage, copays, restrictive policies barriers to vital eye care for adults.

According to the company, the priority review voucher would be issued upon approval of ATSN-201, a gene therapy product candidate.

The LIGHTHOUSE study a Phase I/II, open-label, dose-escalation and dose-expansion clinical trial is currently investigating the safety and tolerability of ASTN-201 for XLRS.

US District Court Judge Anne Nardacci, presiding in the Northern District of New York, ruled David Kwiat, MD, and Kwiat Eye and Laser Surgery PLLC illegally retaliated against the employee based on protected activity.

Physicians share comprehensive approaches during roundtable discussion.